Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 212 clinical trials
HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt. (HDMM)

This is a non-randomized prospective open-label single-arm clinical phase I trial investigating dose finding, feasibility and safety of the combined treatment of HDM201 and midostaurin in patients with relapsed/refractory acute myeloid leukemia (AML) with FLT3mut applying an accelerated titration design.

  • 0 views
  • 24 Mar, 2022
  • 1 location
Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer

This is a prospective, multicenter, multi-arm, non-randomized, open-label clinical trial to evaluate the efficacy and safety of neoadjuvant intensive endocrine therapy for high-risk or locally progressive prostate cancer.

  • 0 views
  • 27 Jul, 2022
  • 1 location
Induction Study #2 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

This is a study to explore the effect of oral ozanimod as an induction treatment for participants with moderately to severely active Crohn's Disease.

immunomodulators
ileal disease
corticosteroids
endoscopy
abdominal pain
  • 550 views
  • 16 Sep, 2022
  • 354 locations
Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

This is a study to explore the effect of oral ozanimod as an induction treatment for participants with moderately to severely active Crohn's Disease.

immunomodulators
ileal disease
corticosteroids
endoscopy
abdominal pain
  • 918 views
  • 20 Sep, 2022
  • 387 locations
Rituximab Maintenance Treatment of Newly Diagnosed Follicular Lymphoma After BR or RCHOP or R2: a Multicenter Clinical Study

This multi-center clinical study will evaluate the efficacy of Rituximab maintenance treatment of newly diagnosed follicular lymphoma after induction therapy of BR, RCHOP or R2.

  • 8 views
  • 21 Apr, 2021
  • 1 location
A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy (HOVON150AML)

AML and MDS-EB2 are malignancies of the bone marrow. The standard treatment for these diseases is chemotherapy. Patients participating have a special type of this disease because the leukemia cells (blasts) have developed an error in the genetic material (DNA). This error is called an IDH1 mutation or an IDH2 …

IDH2
gilbert's syndrome
neoadjuvant therapy
enasidenib
hematologic disorder
  • 47 views
  • 12 Feb, 2022
  • 141 locations
A Phase III, Randomized, Open-Label, Multicenter Study of Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab as Maintenance Therapy in Participants With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following First-Line Induction Therapy With Carboplatin, Etoposide and Atezolizumab (IMforte)

participants with extensive-stage small-cell lung cancer (ES-SCLC) after first-line induction therapy with carboplatin, etoposide, and atezolizumab. The study consists of 2 phases: an induction phase and a

atezolizumab
prophylactic cranial irradiation
carboplatin
lurbinectedin
etoposide
  • 2 views
  • 18 Sep, 2022
  • 72 locations
Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AML

intermediate dose of cytarabine. In the control arm, patients receive DA regimen with standard dose of cytarabine.The efficacy of induction therapy containing intermediate dose of cytarabine is evaluated and

neoadjuvant therapy
cytarabine/daunorubicin
cytarabine
daunorubicin
adult acute myelogenous leukemia
  • 36 views
  • 25 Feb, 2022
  • 1 location
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma (LBL 2018)

decreased by a modified induction therapy including dexamethasone (experimental arm) instead of prednisone (standard arm) Randomization R2, only patients with high risk LBL eligible: to examine

  • 0 views
  • 05 Mar, 2022
  • 70 locations
  • 125 views
  • 22 Mar, 2022
  • 35 locations